Karlheinz Schmelig

Blueprint Genetics is a genetic diagnostics company focused on inherited diseases. We provide world-class genetic diagnostics and clinical interpretation for hereditary diseases. We are passionate about changing peoples’ lives through development of groundbreaking solutions that take genetic diagnostics from niche to mainstream. Our global team of innovative and motivated people are working at the forefront of genetic knowledge, AI and other areas of life science. Our team consists of more than 20 nationalities working as geneticists, data analysts, laboratory technicians, client service specialists, genetic services consultants, software developers and marketing specialists. Today, we work with customers in over 70 countries and push to make genetic knowledge easier to access for the medical community. Our comprehensive and cost-effective genetic tests support healthcare professionals around the world in providing the best care for patients and families with rare inherited diseases.

AYOXXA - The translational proteomics company AYOXXA Biosystems GmbH, based in Cologne (Germany), is an international biotech company focused on the development of its proprietary beads-on-a-chip technology for advanced protein analysis. LUNARIS™. AYOXXA’s innovative multiplex protein analysis platform is a fully integrated system designed for the parallel analysis of multiple biomarkers in picogram amounts of biological samples, allowing scientists to gain a maximum of high quality and reproducible insights. LUNARIS™ is fully scalable, with integrated, image-based quality control and transparent data processing and management, enabling translational proteomics by addressing all the needs from basic to clinical research and development. AYOXXA is commercializing and expanding a portfolio of detection kits covering ophthalmology, model-to-man and immuno-oncology applications.

Acousia is a pioneer of novel medicines. Founded in 2012, the company’s experienced and entrepreneurial management team is committed to combating hearing loss. Thanks to its exclusive collaboration agreement with the renowned Translational Hearing Research Group of Tuebingen University Clinic and an ecosystem of experts and CROs, Acousia has made significant strides with its advanced small molecule drug candidates.

Prostatype Genomics offers prostate cancer patients a decision support for the most optimal treatment option! We developed a test system called 'Prostatype® Test System'. The system is based on a gene expression test, which measures the expression of three carefully selected embryonic stem cell genes in prostate cancer core needle biopsies. In conjunction with currently used clinical parameters, the PrTS predicts overall survival in relation to treatment. The Prostatype® Test System helps to choose the optimal treatment strategy for each patient. This secures quality of life for patients with a low risk tumor without jeopardizing safety for patients with aggressive tumors.

Cube Biotech was founded by a team of membrane protein experts. We provide dedicated services and collaborations for membrane protein applications that facilitate structure based drug design: - Expression: in pro- and eukaryotic systems and cell-free - Purification: using standard tags and customized affinity chromatography - Crystallization: using vapour diffusion, LCP, and proprietary CIMP methods To ensure the highest quality in our service offering, we produce our own consumables. Our raw materials are sourced from selected suppliers committed to the highest quality standards. Many consumables that we use in our service are provided to the community, accompanied by dedicated protocols and handbooks, as well as tips and tricks for success. As a small, flexible company, we address your needs for standard and customized products at almost any scale. We are looking for long-term collaborations with industrial and academic partners. Contact us to learn more.

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors (AAV, Adenoviral vectors, Lentiviral vectors,), vaccines and complex recombinant proteins. With the ELEVECTA® Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents and cGMP plasmids. CEVEC’s CAP® Technology based on human suspension cells is the ideal production platform for RCA-free Adenoviral vectors, Lentiviral vectors, Oncolytic viruses, Viral vaccines and exosomes. With the CAP-Go® Technology CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors and plasma proteins.

SIRION Biotech was founded in 2005 with the goal to spark a new generation of viral vector technologies for gene and cell therapy as well as vaccine development. SIRION evolves novel therapeutic viral vectors and uses proprietary technology platforms based on lenti-, adeno-, and adeno-associated viruses to expedite its partners’ advances in drug development. For additional information, please visit www.sirion-biotech.com.

ALRISE develops controlled release depot formulations for protein, peptide and small molecule drugs. The cornerstone of ALRISE’s business is its patented parenteral drug delivery technology ImSus® for the encapsulation of active pharmaceutical ingredients in biodegradable polymeric nano- or microparticles. ALRISE offers its technology and experience to pharma-, biotech- and generic drug companies with the objective of developing new products or improving current products based on controlled release formulations. Business Areas The development of innovative solutions for target product profiles given by its partners is ALRISE’s core competence. Services mainly apply to areas of - Formulation of New Chemical Entities (in co-operation with drug developing companies) - Reformulation of pharmaceutical products in the context of Product Lifecycle Management (in co-operation with originators) - Reformulation of off-patent drugs to develop supergeneric products (in co-operation with generics companies)

Creathor Ventures invests in technology-oriented companies that drive the automation of industry and business, and the personalization and digitalization of healthcare. The regional focus is on Germany and Switzerland. From its locations in Bad Homburg and Zurich, the team currently supports over 30 tech and healthcare companies. Over the past 30 years, the management team has financed over 200 companies as lead or co-lead investors. More than 20 companies have been listed on international stock exchanges. Creathor Ventures currently manages a fund volume of over 230 million euros.

Blueprint Genetics is a genetic diagnostics company focused on inherited diseases. We provide world-class genetic diagnostics and clinical interpretation for hereditary diseases. We are passionate about changing peoples’ lives through development of groundbreaking solutions that take genetic diagnostics from niche to mainstream. Our global team of innovative and motivated people are working at the forefront of genetic knowledge, AI and other areas of life science. Our team consists of more than 20 nationalities working as geneticists, data analysts, laboratory technicians, client service specialists, genetic services consultants, software developers and marketing specialists. Today, we work with customers in over 70 countries and push to make genetic knowledge easier to access for the medical community. Our comprehensive and cost-effective genetic tests support healthcare professionals around the world in providing the best care for patients and families with rare inherited diseases.

AYOXXA - The translational proteomics company AYOXXA Biosystems GmbH, based in Cologne (Germany), is an international biotech company focused on the development of its proprietary beads-on-a-chip technology for advanced protein analysis. LUNARIS™. AYOXXA’s innovative multiplex protein analysis platform is a fully integrated system designed for the parallel analysis of multiple biomarkers in picogram amounts of biological samples, allowing scientists to gain a maximum of high quality and reproducible insights. LUNARIS™ is fully scalable, with integrated, image-based quality control and transparent data processing and management, enabling translational proteomics by addressing all the needs from basic to clinical research and development. AYOXXA is commercializing and expanding a portfolio of detection kits covering ophthalmology, model-to-man and immuno-oncology applications.

Acousia is a pioneer of novel medicines. Founded in 2012, the company’s experienced and entrepreneurial management team is committed to combating hearing loss. Thanks to its exclusive collaboration agreement with the renowned Translational Hearing Research Group of Tuebingen University Clinic and an ecosystem of experts and CROs, Acousia has made significant strides with its advanced small molecule drug candidates.